Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1996 Apr 1;183(4):1905-9.
doi: 10.1084/jem.183.4.1905.

Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans

Affiliations
Comparative Study

Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans

G Nussbaum et al. J Exp Med. .

Abstract

Vaccination and infection can elicit protective and nonprotective antibodies to the fungus Cryptococcus neoformans in mice. The effect of nonprotective antibodies on host defense is unknown. In this study we used mixtures of protective and nonprotective monoclonal antibodies (mAbs) to determine if nonprotective mAbs blocked the activity of the protective mAbs. Antibody isotype and epitope specificity are important in determining the ability to prolong survival in mice given a lethal C. neoformans infection. Three different nonprotective immunoglobulin (Ig) G23 mAbs to cryptococcal capsular polysaccharide were used to study the interaction between the IgG3 isotype and protective IgG1 and IgG2a mAbs in murine cryptococcal infection. One IgG3 mAb reduced the protective efficacy of an IgG1 with identical epitope specificity. A second IgG3 mAb with different epitope specificity also reduced the protection provided by the IgG1 mAb. The protective efficacy of an IgG2a mAb was also dramatically decreased by still another IgG3 mAb. To our knowledge this is the first report of blocking antibodies to a fungal pathogen. The results have important implications for the development of vaccines and passive antibody therapy against C. neoformans.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Clin Exp Immunol. 1975 Jan;19(1):121-30 - PubMed
    1. Infect Immun. 1995 Jul;63(7):2714-9 - PubMed
    1. J Infect Dis. 1979 Oct;140(4):527-33 - PubMed
    1. J Exp Med. 1980 Apr 1;151(4):853-62 - PubMed
    1. Mol Immunol. 1980 Aug;17(8):1025-32 - PubMed

Publication types

MeSH terms